Article
San Francisco--Still known primarily for its ability to smoothfacial wrinkles, botulinum toxin A (Botox) is gaining acceptance as a treatmentoption for refractory overactive and neurogenic bladder.
Seeds vs. prostatectomy: Long- and short-term side effects differ slightly
Brachytherapy offers high 8-year prostate Ca survival rates
Research on bladder tissue regeneration progresses
Radiation therapy combination prolongs long-term cure rate in men with PCa
Gastric bypass surgery may increase kidney stone risk
Cystectomy outcomes: Does surgeon's age matter?
Study results show CVAC 2.0 is safe, efficacious for wide range of kidney stones
FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC
FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk
Pivotal trial launches of 64Cu-SAR-bisPSMA in BCR of prostate cancer